Is CMPS or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Compass Pathways N/A -49.63% -13.08% Lantheus 17.69% 28.10% 14.35%

Does the media favor CMPS or LNTH?

In the previous week, Compass Pathways and Compass Pathways both had 3 articles in the media. Compass Pathways' average media sentiment score of 0.41 beat Lantheus' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Pathways 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AMRX or CMPS?

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Compass Pathways. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 3 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.41 beat Amneal Pharmaceuticals' score of 0.38 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, BLTE or CMPS?

Belite Bio is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is BLTE or CMPS more profitable?

Belite Bio's return on equity of -11.84% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Compass Pathways N/A -49.63% -13.08%

Does the media refer more to BLTE or CMPS?

In the previous week, Belite Bio had 2 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.41 beat Belite Bio's score of 0.39 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, DFTX or CMPS?

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is DFTX or CMPS more profitable?

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -84.01% -63.66% Compass Pathways N/A -49.63% -13.08%

Does the media favor DFTX or CMPS?

In the previous week, Definium Therapeutics had 1 more articles in the media than Compass Pathways. MarketBeat recorded 4 mentions for Definium Therapeutics and 3 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.41 beat Definium Therapeutics' score of 0.28 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, MANE or CMPS?

Veradermics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A -$70M -$1.90 N/A Compass Pathways N/A N/A -$287.86M -$4.62 N/A

Is MANE or CMPS more profitable?

Veradermics' return on equity of 0.00% beat Compass Pathways' return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A Compass Pathways N/A -49.63% -13.08%

Does the media refer more to MANE or CMPS?

In the previous week, Veradermics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Veradermics and 3 mentions for Compass Pathways. Veradermics' average media sentiment score of 0.47 beat Compass Pathways' score of 0.41 indicating that Veradermics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Compass Pathways (CMPS) Competitors

$12.00 +0.53 (+4.62%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$12.02 +0.03 (+0.21%)

As of 10/9/2026 07:55 PM Eastern

Compare

CMPS vs. LNTH, AMRX, BLTE, DFTX, and MANE

Should you buy Compass Pathways stock or one of its competitors? Compass Pathways's main competitors and comparable companies include Lantheus (LNTH), Amneal Pharmaceuticals (AMRX), Belite Bio (BLTE), Definium Therapeutics (DFTX), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Compass Pathways compare to Lantheus?

Compass Pathways (NASDAQ:CMPS) and Lantheus (NASDAQ:LNTH) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Compass Pathways has a beta of 2.55, indicating that its share price is 155% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Compass Pathways' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compass Pathways	N/A	-49.63%	-13.08%
Lantheus	17.69%	28.10%	14.35%

In the previous week, Compass Pathways and Compass Pathways both had 3 articles in the media. Compass Pathways' average media sentiment score of 0.41 beat Lantheus' score of 0.00 indicating that Compass Pathways is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compass Pathways currently has a consensus price target of $23.36, indicating a potential upside of 94.64%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.95%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

46.2% of Compass Pathways shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.8% of Compass Pathways shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lantheus has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.19

Summary

Lantheus beats Compass Pathways on 8 of the 15 factors compared between the two stocks.

How does Compass Pathways compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Amneal Pharmaceuticals has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	2.11	$72.06M	$0.49	40.63
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Amneal Pharmaceuticals has a net margin of 5.05% compared to Compass Pathways' net margin of 0.00%. Compass Pathways' return on equity of -49.63% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Compass Pathways	N/A	-49.63%	-13.08%

Amneal Pharmaceuticals has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Amneal Pharmaceuticals presently has a consensus target price of $21.00, indicating a potential upside of 5.47%. Compass Pathways has a consensus target price of $23.36, indicating a potential upside of 94.64%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts clearly believe Compass Pathways is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Compass Pathways. MarketBeat recorded 7 mentions for Amneal Pharmaceuticals and 3 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.41 beat Amneal Pharmaceuticals' score of 0.38 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amneal Pharmaceuticals and Compass Pathways tied by winning 8 of the 16 factors compared between the two stocks.

How does Compass Pathways compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market.

Belite Bio is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Belite Bio's return on equity of -11.84% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Compass Pathways	N/A	-49.63%	-13.08%

Belite Bio presently has a consensus price target of $218.73, indicating a potential upside of 41.58%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 94.64%. Given Compass Pathways' stronger consensus rating and higher possible upside, analysts plainly believe Compass Pathways is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Belite Bio had 2 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Belite Bio and 3 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.41 beat Belite Bio's score of 0.39 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Compass Pathways beats Belite Bio on 8 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Compass Pathways' return on equity of -49.63% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Compass Pathways	N/A	-49.63%	-13.08%

In the previous week, Definium Therapeutics had 1 more articles in the media than Compass Pathways. MarketBeat recorded 4 mentions for Definium Therapeutics and 3 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 0.41 beat Definium Therapeutics' score of 0.28 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.9% of Definium Therapeutics shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 2.4% of Definium Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Definium Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 78.86%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 94.64%. Given Compass Pathways' higher probable upside, analysts plainly believe Compass Pathways is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	3.00
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Definium Therapeutics has a beta of 2.19, meaning that its stock price is 119% more volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.55, meaning that its stock price is 155% more volatile than the broader market.

Definium Therapeutics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Summary

Compass Pathways beats Definium Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Compass Pathways compare to Veradermics?

Veradermics (NYSE:MANE) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Veradermics presently has a consensus price target of $153.00, indicating a potential upside of 17.00%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 94.64%. Given Compass Pathways' stronger consensus rating and higher probable upside, analysts plainly believe Compass Pathways is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

46.2% of Compass Pathways shares are owned by institutional investors. 2.8% of Compass Pathways shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Veradermics had 2 more articles in the media than Compass Pathways. MarketBeat recorded 5 mentions for Veradermics and 3 mentions for Compass Pathways. Veradermics' average media sentiment score of 0.47 beat Compass Pathways' score of 0.41 indicating that Veradermics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veradermics' return on equity of 0.00% beat Compass Pathways' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Compass Pathways	N/A	-49.63%	-13.08%

Veradermics is trading at a lower price-to-earnings ratio than Compass Pathways, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

Summary

Compass Pathways beats Veradermics on 7 of the 13 factors compared between the two stocks.

Get Compass Pathways News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMPS vs. The Competition

Export

Metric	Compass Pathways	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.59B	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-2.60	797.58	274.15	26.16
Price / Sales	N/A	939.82	635.98	112.53
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	-21.82	10.71	11.21	6.34
Net Income	-$287.86M	$2.84B	$3.50B	$381.90M
7 Day Performance	0.84%	-0.93%	-0.90%	-1.41%
1 Month Performance	-15.61%	-4.91%	-4.44%	-3.48%
1 Year Performance	92.93%	-4.13%	6.96%	1.16%

Compass Pathways Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMPS Compass Pathways	2.3342 of 5 stars	$12.00 +4.6%	$23.36 +94.6%	+86.3%	$1.59B	N/A	N/A	156
LNTH Lantheus	3.1764 of 5 stars	$100.19 +0.2%	$108.11 +7.9%	+91.2%	$6.52B	$1.54B	24.20	1,193
AMRX Amneal Pharmaceuticals	3.5497 of 5 stars	$20.35 +0.2%	$21.00 +3.2%	+93.5%	$6.48B	$3.12B	41.53	8,500	Analyst Downgrade
BLTE Belite Bio	3.0543 of 5 stars	$159.18 -0.2%	$218.73 +37.4%	+96.8%	$6.43B	N/A	N/A	41
DFTX Definium Therapeutics	3.1601 of 5 stars	$36.23 -3.1%	$64.88 +79.1%	+195.2%	$5.03B	N/A	N/A	40	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMPS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compass Pathways (CMPS) Competitors

CMPS vs. LNTH, AMRX, BLTE, DFTX, and MANE

How does Compass Pathways compare to Lantheus?

Summary

How does Compass Pathways compare to Amneal Pharmaceuticals?

Summary

How does Compass Pathways compare to Belite Bio?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Summary

How does Compass Pathways compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compass Pathways (CMPS) Competitors

CMPS vs. LNTH, AMRX, BLTE, DFTX, and MANE

How does Compass Pathways compare to Lantheus?

Which has more volatility & risk, CMPS or LNTH?

Is CMPS or LNTH more profitable?

Does the media favor CMPS or LNTH?

Do analysts prefer CMPS or LNTH?

Do institutionals & insiders believe in CMPS or LNTH?

Which has better earnings and valuation, CMPS or LNTH?

Summary

How does Compass Pathways compare to Amneal Pharmaceuticals?

Which has better earnings & valuation, AMRX or CMPS?

Is AMRX or CMPS more profitable?

Which has more risk & volatility, AMRX or CMPS?

Do institutionals & insiders have more ownership in AMRX or CMPS?

Do analysts prefer AMRX or CMPS?

Does the media favor AMRX or CMPS?

Summary

How does Compass Pathways compare to Belite Bio?

Which has more volatility & risk, BLTE or CMPS?

Which has preferable valuation and earnings, BLTE or CMPS?

Is BLTE or CMPS more profitable?

Do analysts rate BLTE or CMPS?

Does the media refer more to BLTE or CMPS?

Do institutionals & insiders believe in BLTE or CMPS?

Summary

How does Compass Pathways compare to Definium Therapeutics?

Is DFTX or CMPS more profitable?

Does the media favor DFTX or CMPS?

Do insiders and institutionals believe in DFTX or CMPS?

Do analysts prefer DFTX or CMPS?

Which has more volatility & risk, DFTX or CMPS?

Which has stronger valuation and earnings, DFTX or CMPS?

Summary

How does Compass Pathways compare to Veradermics?

Do analysts prefer MANE or CMPS?

Do institutionals and insiders have more ownership in MANE or CMPS?

Does the media refer more to MANE or CMPS?

Is MANE or CMPS more profitable?

Which has stronger valuation & earnings, MANE or CMPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPS vs. The Competition

Compass Pathways Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools